abstract |
A method for treating liver fibrosis using a CCR2 antagonist is provided. Liver fibrosis may be associated with nonalcoholic fatty liver disease (NASH), nonalcoholic fatty liver disease (NAFLD), new cirrhosis, noncancerous hepatic fibrosis, type 2 diabetes (T2DM) or metabolic syndrome (MS). |